Related Experiment Videos
Advances in post-translational and epigenetic modification of hyperuricemia-to-gout progression: mechanisms and
Wei Fu1, Xiangman Xu1, Xinze Li1
1Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Abstract:
Hyperuricemia (HUA) and gout are endocrine disorders resulting from abnormal uric acid (UA) metabolism, with gout typically developing secondary to HUA and being associated with an exacerbated inflammatory response. Epigenetic modifications and post-translational modifications (PTMs) may contribute to the progression from HUA to gout by modulating the function of UA transporters such as ABCG2 and GLUT9 and involving the NLRP3/IL-β inflammatory axis. However, the specific mechanisms underlying these processes remain incompletely understood. Therefore, this review systematically examines recent research on epigenetic modifications, such as methylation, lactylation, and crotonylation, as well as PTMs including succinylation, phosphorylation, glycosylation, ubiquitination, and acetylation in this process, with the aim of identifying potential therapeutic targets for these two diseases.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu